Hypoxia drives trastuzumab resistance through Rac1 pathway in HER2-positive breast cancer
Virginia Judith Wolos, Giulia Rocca, Marianela Abrigo, Marcela Solange Villaverde, Ezequiel Lacunza, Carla Pulero, Georgina Alexandra Cardama, Giorgio Arrigoni, Gabriel L. Fiszman
This study identifies hypoxia-driven Rac1 pathway activation as a mechanism of trastuzumab resistance in HER2-positive breast cancer and shows Rac1 inhibition can restore drug sensitivity.
bioRxiv · May 9, 2026 · PreprintCancer Biology